Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$255.36 -0.60 (-0.23%)
At close: Sep 28, 2026 · 4:00 PM EDT

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)

Updated

Alnylam Pharmaceuticals' Accumulated Expenses was $1.1 billion in Q2 2026, up 19.3% from $918.97 million a year earlier and up 15.8% from the prior quarter.

Analysis

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026) Analysis & Trends

At the end of FY2025, Accumulated Expenses at Alnylam Pharmaceuticals came in at $1.08 billion, up 36.1% from FY2024.

  • Accumulated Expenses has now increased for 13 consecutive years, with a five-year compound annual growth rate of 24.9% (FY2020 to FY2025).
  • In earlier years, Accumulated Expenses was $793.69 million in FY2024 (+11.3%), $713.01 million in FY2023 (+30.7%), $545.46 million in FY2022 (+38.0%) and $395.17 million in FY2021 (+11.0%).
  • Quarterly Accumulated Expenses has moved between $355.94 million (Q1 2022) and $1.15 billion (Q3 2025) over five years.
  • Compared with a year earlier, Accumulated Expenses has increased for 43 straight quarters, with growth averaging 21.3% over the last eight quarters.
  • The year-over-year growth in Accumulated Expenses has ranged between 0.8% (Q1 2025) and 42.9% (Q1 2023) over the last five years.
  • Per Business Quant data, ALNY's Accumulated Expenses in the three quarters before Q2 2026 was $946.49 million (Q1 2026), $1.08 billion (Q4 2025) and $1.15 billion (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn
10 Alnylam Pharmaceuticals 34.23 Bn 22.28 Bn 992.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.10 Bn
Mar 31, 2026 946.49 Mn
Dec 31, 2025 1.08 Bn
Sep 30, 2025 1.15 Bn
Jun 30, 2025 918.97 Mn
Mar 31, 2025 704.17 Mn
Dec 31, 2024 793.69 Mn
Sep 30, 2024 946.17 Mn
Jun 30, 2024 808.64 Mn
Mar 31, 2024 698.87 Mn
Dec 31, 2023 713.01 Mn
Sep 30, 2023 713.09 Mn
Jun 30, 2023 598.53 Mn
Mar 31, 2023 508.60 Mn
Dec 31, 2022 545.46 Mn
Sep 30, 2022 510.58 Mn
Jun 30, 2022 421.24 Mn
Mar 31, 2022 355.94 Mn
Dec 31, 2021 395.17 Mn
Sep 30, 2021 388.58 Mn
API Access

Alnylam Pharmaceuticals Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=ALNY&period=max&api_key=YOUR_API_KEY